Abstract: The present invention relates to the use of substituted dihydroimidazolones, particularly [1-(4-Chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one] (AWD 131-138) or a physiologically acceptable salt thereof for the treatment of epilepsy in dogs.

Abstract: The present invention relates to the use of substituted dihydroimidazolones, particularly [1-(4-Chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one] (AWD 131-138) or a physiologically acceptable salt thereof for the treatment of epilepsy in dogs.

Abstract: The present invention relates to the use of substituted dihydroimidazolones, particularly [1-(4-Chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one] (AWD 131-138) or a physiologically acceptable salt thereof for the treatment of epilepsy in dogs.

Abstract: The present invention relates to the use of substituted dihydroimidazolones, particularly [1-(4-Chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one] (AWD 131-138) or a physiologically acceptable salt thereof for the treatment of epilepsy in dogs.

Abstract: The present invention relates to the use of substituted dihydroimidazolones, particularly [1-(4-Chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one] (AWD 131-138) or a physiologically acceptable salt thereof for the treatment of epilepsy in dogs.

Abstract: The present invention relates to the use of substituted dihydroimidazolones, particularly [1-(4-Chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1 H-imidazol-2-one] (AWD 131-138) or a physiologically acceptable salt thereof for the treatment of epilepsy in dogs.

Abstract: The present invention relates to the use of substituted dihydroimidazolones, particularly [1-(4-Chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one] (AWD 131-138) or a physiologically acceptable salt thereof for the treatment of epilepsy in dogs.

Abstract: The invention relates to 2,5-dihydropyrazolo[3,4-d]pyrimidin-4-ones and their tautomers which contain in the 5-position an ar(alkyl) radical and in the 2-position a hydrogen or an ar(alkyl) radical, processes for their preparation and their use as medicaments, in particular for the treatment of epilepsy of various forms.

Abstract: A process for the production of 1,2,4-triaminobenzene carbamic acid esters is described, said process being characterised by the use of pyrocarbonate or polypyrocarbonate. The use of pyrocarbonate or polypyrocarbonate brings about a rise in yield and increased purity of the product.

Abstract: The invention relates to 1,5-dihydropyrrol-2-ones of Formula 1 which contain an aryl radical in the 1-position and a secondary amine radical in the 4-position, to a process for making and for a process to treat various forms of epilepsies and of states of anxiety and tension.

Abstract: The invention relates to 3,6-dihydropyrazolo[3,4-d][1,2,3]triazin-4-ones and their tautomers, which contain a benzyl radical in the 6 position, processes for their preparation and their use as medicaments, in particular for the treatment of epilepsy of various forms.

Abstract: Antiepileptic compounds of the formula ##STR1## wherein X is hydrogen, a C.sub.1-4 alkyl, C.sub.1-4 alkoxy, trifluoromethyl, trifluoromethoxy or halogen residue, A is an amino, C.sub.1-4 alkylamino, C.sub.1-4 dialkylamino, morpholino, piperidino or pyrrolidino residue, and n is a cardinal number from 0 to 5, and process for preparing the foregoing compounds and for their use as anticonvulsives.

Abstract: The invention relates to pyrazolo[3,4d]pyrimidin-4(5H)-ones and pyrazolo[3,4-d]pyrimidine-4(5H)-thiones and their tautomers and pharmaceutically acceptable salts, which contain a benzyl radical in the 2-position, processes for their preparation and their use as medicaments, in particular for the treatment of epilepsies of various forms and of allergic/asthmatic diseases.

Abstract: A process for the treatment of anxiety and tension, which comprises administering to a patient in need therefor an anxiolytically effective amount of a compound of the formula ##STR1## wherein X is hydrogen, a C.sub.1-4 alkyl, C.sub.1-4 alkoxy, trifluoromethyl residue, or halogen; R.sup.1 and R.sup.2 are independently of each other a C.sub.1-4 alkyl, cycloalkyl, C.sub.2-4 hydroxyalkyl, or heteroalkyl residue, or R.sup.1 and R.sup.2 together form a C.sub.2-6 alkylene residue in which one --CH.sub.2 -- group can be replaced by oxygen, nitrogen or sulfur; n is 0 or 1, and m is 0 or a cardinal number from 1-5, or a pharmaceutically acceptable salt of the compound.

Abstract: Compounds having anticonsulive activity, of the formula 1 ##STR1## in which X is hydrogen, a C.sub.1-4 -alkyl, C.sub.1-4 alkoxy, trifluoromethyl, or halogen residue, R.sup.1 and R.sup.2 are independently of each other C.sub.1-4 -alkyl, C.sub.2-4 hydroxyalkyl, cycloalkyl or heteroalkyl, or R.sup.1 and R.sup.2 are together a C.sub.2-6 alkylene reside in which a--CH.sub.2 --group is optionally replaced by oxygen, nitrogen or sulfur, m is 0 or 1, and n is 0 or a cardinal number from 1 to 5, and their pharmaceutically acceptable salts. The application also relates to a process for making the compound of formula (I).

Abstract: Anticonvulsive compounds and compositions, of the formula ##STR1## in which X is a C.sub.1-4 -alkyl, trifluoromethyl, or halogen residue, Y is hydrogen or halogen, n is 0 or 1, and m is 0 or a cardinal number from 1 to 4, and its pharmacologically acceptable acid addition salts.

Abstract: A process for producing pharmacologically active 1-unsubstituted 3-aminopyrroles of the formula ##STR1## by ring transformation of a corresponding 1,2-thiazolium pyrrole in a single step, without producing harmful byproducts.